REG - Hemogenyx Pharma Plc - Manufacturing Partnership with Made Scientific

Hemogenyx PharmaceuticalsAnnouncement

08/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH3797Ya&default-theme=true

RNS Number : 3797Y  Hemogenyx Pharmaceuticals PLC  08 September 2025

 

8 September 2025

 

Hemogenyx Pharmaceuticals plc

 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made
Scientific to Advance HG-CT-1 CAR-T Therapy

Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce a
manufacturing partnership with Made Scientific, a leading U.S.-based cell
therapy contract development and manufacturing organization (CDMO), to advance
HG-CT-1, the Company's autologous Chimeric Antigen Receptor T-cell (CAR-T)
therapy for the treatment of relapsed/refractory acute myeloid leukemia (r/r
AML) in adults.

Under the agreement, Hemogenyx Pharmaceuticals will leverage Made Scientific's
specialized expertise in CAR-T cell therapy technology transfer and
manufacturing at its GMP facilities in Newark and Princeton, NJ, which are
equipped for both clinical and commercial supply of cell therapies. The
collaboration is expected to accelerate Company's ongoing Phase I clinical
trial of HG-CT-1 in adult patients and to support the potential inclusion of
additional cohorts for pediatric r/r AML patients.

The Company has already made significant progress in the trial, with early
clinical data supporting growing confidence in both safety and potential
efficacy.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"Partnering with a trusted CDMO like Made Scientific is essential to the
success of HG-CT-1, our lead CAR-T therapy. Made's expertise in cell therapy
manufacturing will be instrumental in driving the continued progress of this
potentially breakthrough therapy for patients with relapsed or refractory AML,
fully in line with our identity as a life saving company."

Syed T. Husain, Chairman & CEO of Made Scientific, said:

"Our collaboration with Hemogenyx Pharmaceuticals reflects Made Scientific's
commitment to advancing next-generation cell therapies that address urgent,
unmet medical needs. Through our integrated development and manufacturing
solutions and highly experienced team, we are proud to support Hemogenyx
Pharmaceuticals as they advance HG-CT-1 in their Phase I clinical trial."

 

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

 

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

 

About Made Scientific
Made Scientific is a leading US-based cell therapy contract development and
manufacturing organization (CDMO) specializing in the development,
manufacturing, and release of autologous and allogeneic cell therapy products
for clinical and commercial supply. Operating from two U.S.-based
manufacturing facilities, Made Scientific combines the agility and
entrepreneurial spirit of a specialist CDMO with the global expertise and
resources of GC Corporation of South Korea, a global leader in the
pharmaceutical and biotechnology sectors.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFZGGLMNDGKZZ